<a href="https://www.fiercebiotech.com/biotech/fueled-ma-and-partnerships-biotech-poised-continued-growth-ey" hreflang="en">Fueled by M&A and partnerships, biotech is poised for continued growth: EY</a>
Ernst & Young projects that biotech revenues will grow by at least 12% in 2026, driven by increased M&A activity and partnerships, despite ongoing challenges such as economic pressures and regulatory uncertainties. The industry is witnessing a decrease in the number of companies but an uptick in funding and innovation, particularly with the integration of AI in R&D processes.
For a professional interested in healthtech and biotech sectors, the key insight is that M&A and partnerships are the primary drivers of confidence and growth in the biotech industry, with a projected 12% revenue increase in 2026. This indicates a strategic opportunity for investment and collaboration, especially in light of the increasing role of AI in biopharma R&D. Focusing on partnerships, particularly with innovative Chinese biotech firms, could be a fruitful strategy given their significant share in U.S. biobucks in 2025.